No Data
No Data
Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Incyte Says Phase 3 InMIND Trial Met Primary Endpoint of PFS
Express News | Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)